Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: Under the agreement, Emergent BioSolutions will no longer enforce a contract that had allowed it to be the only company to develop a nasal spray version of the drug nalmefene for use as an antidote in a nasal spray. The attorney general’s office said the new agreement came after it found that Adapt Pharma, which has since been bought by Rockville, Maryland-based Emergent, had the exclusive rights to sell the drug using Aptar Pharma’s nasal spray technology. The drug is still in the pipeline and is not on the market, though. “Given the tragic, devastating effects of the opioid crisis, and the urgent need for additional drugs for the emergency treatment of opioid overdoses, my office will do whatever possible to ensure that there are no unnecessary impediments to the development of additional life-saving opioid overdose reversal drugs,” Attorney General Letitia James said in a written statement. The agreement with James’s office does not affect Narcan, a spray version of the drug naloxone now sold by Emergent. That from is popular for police, firefighters and others to use to try to revive people who are overdosing. It is not subject to an exclusivity agreement on the spray technology. Narcan retails for about $140 for two doses, but the company sells that amount to first responders for $75. More than 400,000 deaths in the U.S. since 2000 have been linked to opioids, a class of drugs that includes heroin, fentanyl, and prescription painkillers such as Vicodin and OxyContin. Companies would still need Food and Drug Administration approval before their products could be on the market. There is at least one effort to introduce a generic version of a naloxone nasal spray. Purdue Pharma, the maker of OxyContin, announced a grant in 2018 for a nonprofit drug company to develop one. ___ This story has been updated to correct that the drug at the center of the agreement is a spray version of nalmefene that is under development, not naloxone. It also clarifies that Narcan is sold to first responders for a lower-than-retail price.

Answer: Deal will let more companies make an overdose antidote spray.


Question: Chaiya, under pressure from health activists and doctors who campaigned to have him sacked, said declaring compulsory licenses on the drugs would save Thailand more than 3 billion baht ($100 million) over the next five years. “The findings have convinced me to go ahead with the CLs since the ministry’s policy is to give patients good access to quality drugs at cheap prices,” Chaiya said of the review by a panel of Health Ministry officials. The decision is a blow to major pharmaceutical companies which had lobbied hard to reverse the CL policy launched by the previous government appointed after a bloodless 2006 coup. The three drugs are Letrozole, a breast cancer medicine made by Novartis AG, the breast and lung cancer drug Docetaxel by Sanofi-Aventis, and Roche’s Erlotinib, used for treating lung, pancreatic and ovarian cancer. A license issued on a leukemia drug, Glivec, was cancelled last month after its maker, Novartis, agreed to supply it free to hundreds of Thai patients. Shortly after a democratically-elected government took power in February, Chaiya ordered the review of a policy he said was a “politically correct decision, but not legally correct”. At the time he said the government could afford the full cost of the drugs, if it meant avoiding trade retaliation by the United States, home to some of the world’s biggest drug firms. U.S. officials denied there were any plans to impose sanctions on Bangkok, although Thailand was placed on a watch list, meaning Washington believed its respect for patents had weakened. When Chaiya, a businessman with no medical training, fired the Health Ministry’s top official negotiating cheaper prices from foreign drug firms, outraged health activists and doctors launched a campaign to remove him. Chaiya said on Monday the ministry would buy cheaper versions of the cancer drugs from generic producers, such as Indian firms which already supply copy-cat HIV-AIDS medicines to Thailand. Under World Trade Organisation rules, countries can issue a compulsory license to make or buy generic versions of patented drugs deemed critical to public health as long as the medicines are meant for domestic use. Former Health Minister Mongkol na Songkhla overrode Merck’s AIDS drug Efavirenz in late 2006, arguing that Thailand could not afford patented drugs for a national health plan that covers about 80 percent of the country’s 63 million people. A few months later he did the same on a Sanofi-Aventis heart medicine and an AIDS drug made by Abbott Laboratories, which refused to register several new medicines in Thailand. Mongkol, who targeted the four cancer drugs weeks before he left office, has defended the CL policy against major drug firms which accused him of stealing their intellectual property rights. ($1= 30 Baht)

Answer: Thailand will override cancer drug patents.


Question: The vaccine protects against HPV, a virus that is commonly spread through sex and can cause certain cancers and genital warts. The Advisory Committee on Immunization Practices’ vote in Atlanta raises the recommended vaccination age for men from 21 to 26, making it the same as the existing recommendation for women. The Centers for Disease Control and Prevention almost always accepts the panel’s recommendations and uses them as guidance for U.S. doctors. The HPV vaccine is usually given to 11- and 12-year olds, to protect them before their first exposure to sexually transmitted viruses. Women as old as 26 had been recommended to get a “catch-up” vaccination if they missed the shots in pre-adolescence. For men, the catch-up recommendation had applied only up to age 21, because research indicates males tend to be exposed to sexually-transmitted viruses earlier. The panel decided Wednesday to equalize the age recommendations to make it easier for doctors. The CDC estimates that roughly half of Americans ages 18 to 59 had some form of genital HPV. Vaccinations against it first became available in 2006 and each dose now costs $216. The vaccine is approved for people up to age 45, but the same panel declined a proposal to recommend it for people older than 26. Instead, it settled on a weak endorsement for adults between 26 and age 45, meaning patients and doctors can make the decision together. It’s not clear how many cancers would be prevented in that age group or whether the cost is worth the public health benefit, experts at the meeting said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Answer:
Vaccine panel gives nod to HPV shots for men up to age 26.